High Macular Fluid volume risk factor for progressive neovascular age-related macular degeneration

Written By :  Dr. Shravani Dali
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2023-12-18 17:30 GMT   |   Update On 2023-12-19 08:55 GMT
Advertisement

High Macular Fluid volume risk factor for progressive neovascular age-related macular degeneration suggests a new study published in the Canadian Journal of Ophthalmology.

A study was done to investigate the effect of macular fluid volumes (subretinal fluid [SRF], intraretinal fluid [IRF], and pigment epithelium detachment [PED]) after initial treatment on functional and structural outcomes in neovascular age-related macular degeneration in a real-world cohort from Fight Retinal Blindness!

Advertisement

Treatment-naive neovascular age-related macular degeneration patients from Fight Retinal Blindness! (Zürich, Switzerland) were included. Macular fluid on optical coherence tomography was automatically quantified using an approved artificial intelligence algorithm. Follow-up of macular fluid, number of anti-vascular endothelial growth factor treatments, effect of fluid volumes after initial treatment (high, top 25%; low, bottom 75%) on best-corrected visual acuity, and development of macular atrophy and fibrosis was investigated over 48 months.

Results

A total of 209 eyes (mean age, 78.3 years) were included. Patients with high IRF volumes after initial treatment differed by –2.6 (p = 0.021) and –7.4 letters (p = 0.007) at months 12 and 48, respectively. Eyes with high IRF received significantly more treatments (+1.6 [p < 0.001] and +5.3 [p = 0.002] at months 12 and 48, respectively). Patients with high SRF or PED had comparable best-corrected visual acuity outcomes but received significantly more treatments for SRF (+2.4 [p < 0.001] and +11.4 [p < 0.001] at months 12 and 48, respectively) and PED (+1.2 [p = 0.001] and +7.8 [p < 0.001] at months 12 and 48, respectively).

Patients with high macular fluid after initial treatment are at risk of losing vision that may not be compensable with higher treatment frequency for IRF. Higher treatment frequency for SRF and PED may result in comparable treatment outcomes. Quantification of macular fluid in all compartments is essential to detect eyes at risk of aggressive disease.

Reference:

Long-term effect of fluid volumes during the maintenance phase in neovascular age-related macular degeneration: results from Fight Retinal Blindness. Gregor S. Reiter, Virginia Mares Oliver Leingang, Hrvoje Bogunovic, Daniel Barthelmes, Ursula Schmidt-Erfurth

Open AccessPublished:November 18, 2023DOI:https://doi.org/10.1016/j.jcjo.2023.10.017

Keywords:

Long-term, effect, fluid, volumes, during, maintenance, phase, neovascular, age-related, macular, degeneration, results, Fight, Retinal, Blindness, Gregor S. Reiter, Virginia Mares Oliver Leingang, Hrvoje Bogunovic, Daniel Barthelmes, Ursula Schmidt-Erfurth, Canadian Journal of Ophthalmology

Tags:    
Article Source : Canadian Journal of Ophthalmology

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News